Featured Research Search Results
Research Study on the Genetics of Breast Cancer
Clinicaltrials.gov identifier:
NCT06773897
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
Clinicaltrials.gov identifier:
NCT06844383
Treatment
Study for metastatic castration-resistant prostate cancer with an HRR mutation
Phase 2
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
Clinicaltrials.gov identifier:
NCT07318363
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
Phase 3
Previvors’ Perceptions of Preimplantation Genetic Testing (PGT-M) After a Cancer Predisposition Diagnosis
Surveys, Registries, Interviews
Interview for eligible previvors
Beyond a "Women's Gene": Assessing the Perception and Satisfaction Following Genetic Counseling for Males with a BRCA Mutation
Surveys, Registries, Interviews
Survey for men with a BRCA1 or BRCA2 genetic mutation
Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations
Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of cancer
Family Study for People with Certain Rare BRCA1 or BRCA2 Variants
Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative
Comparing Treatment with Sacituzumab Govitecan and Bevacizumab to Chemotherapy and Bevacizumab for Recurrent Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Clinicaltrials.gov identifier:
NCT07504588
Treatment
Study for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor
Phase 2
Testing a Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors in People with a BRCA2 Mutation (ERADIC8)
Clinicaltrials.gov identifier:
NCT06395519
Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Phase 1/2
Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer
Clinicaltrials.gov identifier:
NCT06888388
Prevention
Study for people considering double mastectomy to reduce breast cancer risk
A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)
Clinicaltrials.gov identifier:
NCT04294927
Prevention
Prevention study for women at high risk for ovarian cancer
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT05384535
Prevention
Screening for people at high risk for prostate cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Phase 1
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD
Clinicaltrials.gov identifier:
NCT06580314
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
Phase 3
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer
Clinicaltrials.gov identifier:
NCT06952803
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
Phase 3
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Phase 1
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
Phase 3
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Clinicaltrials.gov identifier:
NCT04251052
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries